NASDAQ:SRZN Surrozen (SRZN) Stock Price, News & Analysis $9.56 +0.53 (+5.87%) Closing price 04:00 PM EasternExtended Trading$9.59 +0.03 (+0.26%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Surrozen Stock (NASDAQ:SRZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Surrozen alerts:Sign Up Key Stats Today's Range$9.11▼$9.9550-Day Range$8.13▼$11.0052-Week Range$5.90▼$18.17Volume10,258 shsAverage Volume11,484 shsMarket Capitalization$81.83 millionP/E RatioN/ADividend YieldN/APrice Target$38.50Consensus RatingBuy Company Overview Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. Read More Surrozen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreSRZN MarketRank™: Surrozen scored higher than 52% of companies evaluated by MarketBeat, and ranked 729th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSurrozen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSurrozen has only been the subject of 1 research reports in the past 90 days.Read more about Surrozen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Surrozen are expected to decrease in the coming year, from ($8.49) to ($10.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surrozen is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surrozen is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Surrozen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.62% of the float of Surrozen has been sold short.Short Interest Ratio / Days to CoverSurrozen has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Surrozen has recently increased by 7.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSurrozen does not currently pay a dividend.Dividend GrowthSurrozen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.62% of the float of Surrozen has been sold short.Short Interest Ratio / Days to CoverSurrozen has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Surrozen has recently increased by 7.75%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.60 News SentimentSurrozen has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Surrozen this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Surrozen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Surrozen insiders have not sold or bought any company stock.Percentage Held by Insiders45.18% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Surrozen's insider trading history. Receive SRZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter. Email Address SRZN Stock News HeadlinesSurrozen Reports Q2 Profit on GainsAugust 8 at 5:21 PM | fool.comSurrozen Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 8 at 4:05 PM | globenewswire.comFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft. But one controversial analyst, known for predicting the collapses of Fannie Mae, GM, and others, is issuing a serious warning. He believes Nvidia’s rise has masked a dangerous flaw—and that the stock could fall 50% or more from current levels.August 8 at 2:00 AM | Porter & Company (Ad)Surrozen to Present at Upcoming Healthcare Investor ConferenceAugust 6 at 4:30 PM | globenewswire.comWe Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business GrowthJuly 1, 2025 | finance.yahoo.comSurrozen secures patent for tissue repair technologyMay 15, 2025 | investing.comSurrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt PathwayMay 14, 2025 | globenewswire.comSurrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 10, 2025 | finanznachrichten.deSee More Headlines SRZN Stock Analysis - Frequently Asked Questions How have SRZN shares performed this year? Surrozen's stock was trading at $14.35 at the beginning of 2025. Since then, SRZN stock has decreased by 33.4% and is now trading at $9.56. How were Surrozen's earnings last quarter? Surrozen, Inc. (NASDAQ:SRZN) issued its earnings results on Friday, August, 8th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.09. When did Surrozen's stock split? Surrozen's stock reverse split on Thursday, December 14th 2023.The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Surrozen's major shareholders? Surrozen's top institutional investors include Geode Capital Management LLC (0.36%). Insiders that own company stock include Group Gp Lp Column III, Tim Kutzkey, Yang Li and Charles O Williams. View institutional ownership trends. How do I buy shares of Surrozen? Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Surrozen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Surrozen investors own include ACADIA Pharmaceuticals (ACAD), Marvell Technology (MRVL), HubSpot (HUBS), Avidity Biosciences (RNA), Adverum Biotechnologies (ADVM), Alpha and Omega Semiconductor (AOSL) and Company Calendar Today8/08/2025Last Earnings8/08/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRZN CIK1824893 Webwww.consonancehfw.com Phone650-489-9000FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for Surrozen$38.50 High Price Target$45.00 Low Price Target$32.00 Potential Upside/Downside+302.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($24.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.56 million Net MarginsN/A Pretax Margin-702.04% Return on Equity-842.90% Return on Assets-71.32% Debt Debt-to-Equity RatioN/A Current Ratio10.02 Quick Ratio10.02 Sales & Book Value Annual Sales$10.65 million Price / Sales7.68 Cash FlowN/A Price / Cash FlowN/A Book Value($6.55) per share Price / Book-1.46Miscellaneous Outstanding Shares8,560,000Free Float4,694,000Market Cap$81.83 million OptionableNot Optionable Beta0.60 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:SRZN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.